Post-IPO, Kailera looks beyond obesity to MASH

Kailera is using its first post-IPO clinical update to broaden its story beyond the crowded obesity market. Phase I data from partner Hengrui showed triple GLP-1R/GIPR/GCGR agonist KAI-4729 produced weight loss and liver fat reductions in healthy volunteers, giving the partners a rationale to take the peptide into MASH, where the key question will be whether triple agonism can translate metabolic effects into improvements in liver inflammation and fibrosis.

In April, Kailera Therapeutics Inc. (NASDAQ:KLRA) raised $718.8 million in its IPO after the greenshoe, making it the largest biotech debut offering ever on NASDAQ. On Tuesday, the company’s first quarterly update as a public company included top-line data from a first-in-human trial of KAI-4729 (HRS-4729), which is being developed with Jiangsu Hengrui Pharmaceuticals Co. Ltd. (Shanghai:600276; HKEX:1276)...